Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA)
NCT00882024 is a phase 2 interventional trial sponsored by Nuon Therapeutics, Inc.. As of 21 Nov 2026, it is completed. It studies Placebo and Tranilast in Active Rheumatoid Arthritis. The registry lists an enrollment of 250 participants at 32 sites in 8 countries. The registry lists a start date of 31 Mar 2009 and a primary completion date of 31 Dec 2010.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00882024 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Nuon Therapeutics, Inc. |
| Enrollment | 250 |
| Registered sites | 32 |
| Countries | 8 |
| Conditions | Active Rheumatoid Arthritis |
| Drugs | Placebo and Tranilast |
| Start | 31 Mar 2009 |
| Primary completion | 31 Dec 2010 |
| Study completion | 31 Dec 2010 |
| Last update posted | 6 Jan 2011 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Michael Kitt, MD
Nuon Therapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
32 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Mesa
- Facility name not stated
Paradise Valley
- Facility name not stated
La Jolla
- Facility name not stated
San Diego
- Facility name not stated
Aventura
- Facility name not stated
Frederick
- Facility name not stated
Lansing
- Facility name not stated
Hickory
- Facility name not stated
Duncansville
- Facility name not stated
Hamburg
- Facility name not stated
Ludwigsfelde
- Facility name not stated
Naumburg
- Facility name not stated
Osnabrück
- Facility name not stated
Ratingen
- Facility name not stated
Wiesbaden
- Facility name not stated
Capital Federal, Buenos Aires
- Facility name not stated
Luján, Buenos Aires
- Facility name not stated
Quilmes, Buenos Aires
- Facility name not stated
Rosario, Santa Fe Province
- Facility name not stated
Brno-Bohunice
- Facility name not stated
Ostrava-Hlucin
- Facility name not stated
Prague
- Facility name not stated
Zlín
- Facility name not stated
Mexicali, Estado de Baja California
- Facility name not stated
Guadalajara, Jalisco
- Facility name not stated
Morelia, Michoacán
- Facility name not stated
Obregón, Sonora
- Facility name not stated
Plovdiv
- Facility name not stated
Sofia
- Facility name not stated
Belgrade
- Facility name not stated
Niška Banja
- Facility name not stated
London
United States, by state
Outside the United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00882024
Each answer restates registry values shown on this page.
What is NCT00882024?
NCT00882024 is a phase 2 interventional trial sponsored by Nuon Therapeutics, Inc.. It studies Placebo and Tranilast in Active Rheumatoid Arthritis.
Who leads NCT00882024?
The registry names Michael Kitt, MD (study director, Nuon Therapeutics, Inc.) as the overall official.
Where does NCT00882024 run?
The registry lists 32 sites in 8 countries. Most sites are in these countries: United States (9), Germany (6) and Argentina (4).
Which drugs does NCT00882024 study?
The registered drug and biological interventions are Placebo and Tranilast.
When did NCT00882024 end?
The registry lists a primary completion date of 31 Dec 2010 and a study completion date of 31 Dec 2010. The sponsor last updated the record on 6 Jan 2011.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.